UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049203
Receipt number R000055825
Scientific Title Evaluation of effect on the postprandial glucose elevation and glycemic variability of Imeglimin
Date of disclosure of the study information 2022/10/13
Last modified on 2024/01/25 14:52:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of the efficacy of Imeglimin on glycemic control and the underlying mechanisms

Acronym

IMAGINE
IMeglimin Amplifies Glucose-stimulated INsulin secretion and modifies glycemic Elevation in type 2 diabetes

Scientific Title

Evaluation of effect on the postprandial glucose elevation and glycemic variability of Imeglimin

Scientific Title:Acronym

IMAGINE
IMeglimin Amplifies Glucose-stimulated INsulin secretion and modifies glycemic Elevation in type 2 diabetes

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine of the effect on the postprandial glucose elevation and the glycemic variability of Imeglimin as add-on therapy in patients with type 2 diabetes inadequately controled with DPP-4 inhibitor monotherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The change of the AUC insulin/AUC glucose between pre and post intervention

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Imeglimin 2000mg/day for 12 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

(1)Patients with type 2 diabetes
(2)Patients with an eGFR of 45mL/min/1.73m2 or more
(3)Patients aged 20 to 80
(4)Patients who have the avility to consent to participation in this study and who can understand the consent form and other explanatory documents
(5) Patients who have been treated with monotherapy of DPP-4 inhibitors in the past 3months

Key exclusion criteria

(1)Type 1 diabetes mellitus patients
(2)Patients with severe liver disease or AST (GOT) or ALT (GPT) >100 IU/L
(3)Patients with serious renal disease and patients with a serum creatinine level of 2.0 mg/dL or higher before the start of the study
(4)Patients with overt heart failure and those who had myocardial infarction within 3 months before the start of the study
(5)Patients with severe pancreatic disease
(6)Patients with acute stage/serious condition that may cause change in condition due to blood sugar fluctuation or addition of drugs
(7)Patients with serious infections or serious trauma. Patients before and after surgery
(8)Patients with severe chronic bowel disease accompanied by inflammatory bowel disease, colonic ulcer, focal bowel obstruction, bowel obstruction predisposition, or digestive/absorptive disorders
(9) Excessive habitual drinkers
(10) Pregnant women, women who may be pregnant, women who wish to become pregnant, and women who are breastfeeding
(11) Patients who are judged to be inappropriate by the investigator

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Takahisa
Middle name
Last name Hirose

Organization

Toho University School of Medicine

Division name

Divsion of diabetes, metabolism and endocrinology

Zip code

143-8541

Address

6-11-1 Omori-nishi,Ota-ku,Tokyo 143-8541,Japan

TEL

03-3762-4151

Email

takahisa.hirose@med.toho-u.ac.jp


Public contact

Name of contact person

1st name Atsushi
Middle name
Last name Itsukaichi

Organization

Toho University School of Medicine

Division name

Divsion of diabetes, metabolism and endocrinology

Zip code

143-8541

Address

6-11-1 Omori-nishi,Ota-ku,Tokyo 143-8541,Japan

TEL

03-3762-4151

Homepage URL


Email

atsushi.itsukaichi@med.toho-u.ac.jp


Sponsor or person

Institute

Toho university

Institute

Department

Personal name



Funding Source

Organization

Toho university

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Toho University Medical Center Omori Hospital Ethics Committee Secretariat

Address

6-11-1 Omori-nishi,Ota-ku,Tokyo 143-8541,Japan

Tel

03-5763-6534

Email

omori.rinri@ext.toho-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 10 Month 01 Day

Date of IRB

2022 Year 07 Month 26 Day

Anticipated trial start date

2022 Year 10 Month 13 Day

Last follow-up date

2025 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 10 Month 12 Day

Last modified on

2024 Year 01 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000055825


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name